Stakes Are High for Regeneron's Eylea HD as Genentech's Vabysmo Continues to Gain Momentum, Prompting Doctors to Weigh Their Options Between Two Industry Titans, According to Spherix Global Insights
Wet AMD poses a particularly severe threat to vision, necessitating treatment with biologic therapies administered in four to twelve-week intervals.
- Wet AMD poses a particularly severe threat to vision, necessitating treatment with biologic therapies administered in four to twelve-week intervals.
- However, the current treatment landscape often burdens elderly patients with high treatment frequencies, impacting their ability to attend all appointments.
- Spherix Global Insights conducted an in-depth analysis through its RealTime Dynamix™ report series, delving into the evolving perceptions of ophthalmologists (n=101) regarding approved therapies for wet AMD.
- In January 2024, ophthalmologists were surveyed on their preferred biologic treatment for wet AMD among other topics.